

**Wanbury Limited**

Regd. Office: BSEL Tech Park, B-Wing, 10th Floor, Sector-30A, Opp. Vashi Railway Station, Vashi, Navi Mumbai 400703 Maharashtra, INDIA
Tel: +91-22-6794 2222
+91-22-7196 3222
CIN: L51900MH1988PLC048455
Email: info@wanbury.com
Website: www.wanbury.com

October 30, 2026

BSE Limited PJ. Towers, Dalal Street Mumbai – 400 001. Script Code: 524212	National Stock Exchange of India Ltd, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai -400 051. Script Code: WANBURY
---	---

Dear Sir/Madam,

Sub.: Wanbury Limited Receives Australian TGA GMP Compliance Certificate for its Tanuku Plant, Strengthening Its Global Pharmaceutical Manufacturing Credentials

Pursuant to Regulation 30 of SEBI LODR, we wish to inform you as under:

Please find enclosed the press release regarding receipt of the Australian TGA GMP Compliance Certificate for its Tanuku Plant, Strengthening its Global Pharmaceutical Manufacturing Credentials.

This is for your information and records.

Thanking you.

Yours faithfully,
For Wanbury Limited

JITENDRA
JAYANTILAL
GANDHI
Jitendra J. Gandhi
Company Secretary

Digitally signed by JITENDRA JAYANTILAL GANDHI
DN: cn=JITENDRA JAYANTILAL GANDHI, o=WANBURY LIMITED,
ou=JITENDRA JAYANTILAL GANDHI, email=jgandhi@wanbury.com,
c=IN
Date: 2026.10.30 12:41:56 +05'30'

Encl.: a/a



PRESS RELEASE

Wanbury Limited Receives Australian TGA GMP Compliance Certificate for its Tanuku Plant, Strengthening its Global Pharmaceutical Manufacturing Credentials.

Mumbai, 30 October 2026: Wanbury Limited is pleased to announce that its manufacturing facility at Tanuku, Andhra Pradesh, has successfully received the **Good Manufacturing Practice (GMP) Compliance Certificate from Australia's Therapeutic Goods Administration (TGA)**, the regulatory authority responsible for therapeutic goods in Australia.

The certification marks an important milestone in Wanbury's commitment to manufacturing excellence, stringent quality standards and strengthening its presence in regulated international pharmaceutical markets.

Following a successful inspection conducted by the TGA on **8-9 June 2026**, the Australian regulatory authority confirmed that the manufacturing facility complies with the applicable Good Manufacturing Practice requirements outlined in the PIC/S Guide to Good Manufacturing Practice for Medicinal Products.

The certificate covers the manufacturing of the following six Active Pharmaceutical Ingredients (APIs):

1. Metformin Hydrochloride
2. Tramadol Hydrochloride
3. Sertraline Hydrochloride
4. Diphenhydramine Hydrochloride
5. Mefenamic Acid
6. Paroxetine Hydrochloride Hemihydrate

The certificate was issued on 28 October 2026 and is valid until **9 December 2028**, subject to the TGA's applicable re-inspection requirements.

With this approval, the TGA will proceed with issuing GMP clearances to Australian sponsors associated with the manufacturing facility, enabling the necessary regulatory clearances for the supply of the approved APIs to the Australian market.

A Step Forward in Global Growth

This achievement reinforces Wanbury's focus on building globally compliant manufacturing capabilities and expanding its footprint across international markets. Recognition by a stringent regulatory authority such as Australia's TGA further strengthens the company's quality credentials and its ability to serve customers and partners in regulated pharmaceutical markets.

The certification represents another significant milestone in Wanbury's journey towards operational excellence, regulatory compliance and sustainable business growth.



About Wanbury Ltd:

Established in 1988, listed on the National Stock Exchange of India Ltd (Code: WANBURY) and BSE Ltd (Code: 524212). The company has a strong presence in API global market and domestic branded Formulation with its API being exported to over 50 countries and has Pan-India Formulation presence. The company has USFDA & EUGMP approved facilities at Tanuku (Andhra Pradesh) and Patalganga (Maharashtra).

The API product portfolio includes Antidiabetic, Antidepressant, Pain management, Antihistamine, Anti-inflammatory, Antidepressant and various other products in pipeline. The company's clients include some of the leading global generic players.

In formulations, the company has a wide presence across major therapeutic categories like cough and cold solutions, gynecology, orthopedics, nutraceuticals, gastrointestinal, anti-inflammatory, & analgesics.

For more details on Wanbury Ltd.: <https://www.wanbury.com/>

For any Investor Relations query, please contact:

Jitendra J. Gandhi Company Secretary, Wanbury Limited BSEL Techpark, B' Wing, 10th Floor, Sector 30-A, Opp. Vashi Railway Station, Vashi, Navi Mumbai - 400703, Maharashtra, India. Tel: +91-22-6794 2222 Email: jitendra.gandhi@wanbury.com	Smit Shah / Hanishi Shah Adfactors PR Oasis Complex, Kamala Mills Compound, City Hall, Pandurang Budhkar Marg, Lower Parel West, Mumbai - 400021 Tel : +91 9870789596 / +91 9619059339 Email : smit.shah@adfactorspr.com / hanishi.shah@adfactorspr.com
--	---

Caution Concerning Forward- Looking Statements:

This document may contain statements, which reflect management's current views and estimates and could be construed as forward-looking statements. The future involves certain risks and uncertainties and could cause actual results to differ materially from the current views being expressed. Potential risks and uncertainties include factors such as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.